MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer-Reference-Cited by-同舟云学术

MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer

Published:2021-10 Issue:1 Volume:163 Page:181-190
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Wu Yutuan,Huang Jie,Ivan Cristina,Sun Yunjie,Ma Shaolin,Mangala Lingegowda S.,Fellman Bryan M.,Urbauer Diana L.,Jennings Nicholas B.,Ram Prahlad,Coleman Robert L.,Hu Wei,Sood Anil K.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference28 articles.

1. Lenvatinib plus Pembrolizumab in patients with advanced endometrial cancer;Makker;J. Clin. Oncol.,2020

2. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer;Merritt;Cancer Biol. Ther.,2010

3. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery;Landen;Cancer Res.,2005

4. EphA2 as a target for ovarian cancer therapy;Landen;Expert Opin. Ther. Targets,2005

5. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer;Landen;J. Natl. Cancer Inst.,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in research on autophagy mechanisms in resistance to endometrial cancer treatment;Frontiers in Oncology;2024-03-27

2. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

3. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches;Gynecologic Oncology;2023-10

4. MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA2;Journal of Chemotherapy;2023-05-17

5. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective;Signal Transduction and Targeted Therapy;2022-09-17